既往放疗失败后局部复发前列腺癌的局部挽救性高剂量率近距离放疗:一项前瞻性临床试验结果
这项前瞻性研究纳入15例既往外照射放疗后局部复发的前列腺癌患者,采用超声引导下局部挽救性高剂量率近距离放疗,处方剂量27 Gy分2次植入、间隔1周,针对MRI可见复发灶所在象限。中位随访36个月,仅1例3级泌尿生殖毒性,无尿潴留,3年生化失败无生存率61%,尿路和肠道生活质量无显著变化。作者认为该疗法耐受性好且有前景,需外部验证。
要点
- 15例既往外照射放疗后局部复发前列腺癌患者接受局部挽救性HDR近距离放疗,处方剂量27 Gy分2次植入、间隔1周。
- 中位随访36个月,仅1例3级泌尿生殖毒性,无尿潴留,3年PSA无失败生存率61%。
- 14例治疗后MRI评估中12例有治疗反应,尿路和肠道生活质量评分无显著变化。
核心结论
- 作者认为局部挽救性HDR近距离放疗耐受性好且有前景,但需要外部验证。
研究设计与样本
- 前瞻性临床试验纳入15例既往外照射放疗后局部复发的前列腺癌患者。
- 患者接受超声引导下HDR近距离放疗,处方剂量27 Gy分2次植入、间隔1周,临床靶区为MRI可见复发灶所在的前列腺象限。
- 分析毒性、生活质量和生化结局,治疗后行MRI评估放疗反应。
主要发现
- 中位随访36个月,MRI上复发灶中位大小9 mm(范围7-20 mm),HDR时临床靶区中位体积6.1 mL(范围2.2-16.1 mL)。
- 仅观察到1例3级泌尿生殖毒性事件,未观察到尿潴留。
- 3年前列腺特异性抗原无失败生存率为61%。
- 扩展前列腺癌指数综合评分尿路和肠道领域随时间无显著变化。
- 14例接受治疗后MRI的患者中,12例有治疗反应。
局限性
- 作者指出需要外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although increasing data support whole-gland salvage therapy for recurrent prostate cancer, toxicity remains a significant concern. We hypothesized that focal therapy, treating only a portion of the prostate containing recurrent disease, might be equally effective and associated with less toxicity. The objectives of this prospective study were to explore the toxicities, quality of life, and efficacy of focal salvage high-dose-rate (HDR) brachytherapy in patients with multiparametric magnetic resonance imaging (MRI)-visible, biopsy-confirmed local recurrence after previous definitive external beam radiation therapy. MATERIALS AND METHODS: Fifteen patients with locally recurrent prostate cancer after external beam radiation therapy were enrolled in this prospective study. Patients were treated with ultrasound-based HDR brachytherapy with a prescription dose of 27 Gy divided in 2 implants, separated by 1 week, to the clinical target volume, which was defined as the quadrant of the prostate where the MRI-visible recurrent lesion was located. Toxicity, quality of life, and biochemical outcomes were analyzed. Postsalvage MRI was performed to assess radiation therapy response. RESULTS: Median follow-up was 36 months. The median size of the recurrence on MRI was 9 mm (range, 7-20 mm), and clinical target volume at the time of HDR was 6.1 mL (range, 2.2-16.1 mL). Only one grade 3 genitourinary toxicity event was observed. No urinary retention was observed. Three-year prostate-specific antigen failure-free rate was 61%. There was no significant change in Expanded Prostate Cancer Index Composite urinary or bowel domains over time. Of the 14 patients who had a post-HDR MRI, 12 had a treatment response. CONCLUSIONS: Our results suggest that focal salvage HDR brachytherapy is well tolerated and promising. External validation is needed.
引用
- Murgic J, Morton G, Loblaw A, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 30244878. doi:10.1016/j.ijrobp.2018.06.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。